BioXcel Therapeutics (BTAI) Accumulated Depreciation (2017 - 2026)

BioXcel Therapeutics' Accumulated Depreciation history runs 10 years deep, the most recent figure standing at $1.9 million for Q1 2026.

• In Q1 2026, Accumulated Depreciation rose 17.87% year-over-year to $1.9 million; the TTM figure through Mar 2026 stood at $1.9 million (up 17.87% YoY), while the FY2025 annual figure was $1.8 million, up 19.97% from the prior year.
• Accumulated Depreciation was $1.9 million for Q1 2026 at BioXcel Therapeutics, up from $1.8 million in the prior quarter.
• In the past five years, Accumulated Depreciation ranged from a high of $1.9 million in Q1 2026 to a low of $679000.0 in Q1 2022.
• Historically, Accumulated Depreciation has averaged $1.3 million across 5 years, with a median of $1.3 million in 2024.
• The sharpest annual moves came in 2022 and 2026: Accumulated Depreciation jumped 61.22% in 2022, then advanced 17.87% in 2026.
• A 5-year view of Accumulated Depreciation shows it stood at $885000.0 in 2022, then soared by 34.8% to $1.2 million in 2023, then advanced by 25.9% to $1.5 million in 2024, then increased by 19.97% to $1.8 million in 2025, then climbed by 3.22% to $1.9 million in 2026.
• The last three Accumulated Depreciation figures came in at $1.9 million (Q1 2026), $1.8 million (Q4 2025), and $1.7 million (Q3 2025), per Business Quant data.